Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4

European Journal of Pharmacology

Volumn 468, Issue 1, 2003, Pages 15-19

  Karasawa, Hiroshi ^a,b   Taketo, Makoto M ^a,c   Matsui, Minoru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Catalepsy; Extrapyramidal side effect; Haloperidol; Knockout mouse; Muscarinic receptor; Scopolamine

Indexed keywords

HALOPERIDOL; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RECEPTOR SUBTYPE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHOLINERGIC ACTIVITY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0037728740     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01642-X     Document Type: Article

References (18)

1. Caulfield M.P., Birdsall N.J. International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50:1998;279-290.
2. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl.). 132:1997;107-124.
3. 4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10483-10488.
4. Haraguchi K., Ito K., Kotaki H., Sawada Y., Iga T. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Drug Metab. Dispos. 25:1997;675-684.
5. Hersch S.M., Gutekunst C.A., Rees H.D., Heilman C.J., Levey A.I. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 14:1994;3351-3363.
6. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl.). 120:1995;128-133.
7. Ince E., Ciliax B.J., Levey A.I. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse. 27:1997;357-366.
8. Kanes S.J., Hitzemann B.A., Hitzemann R.J. On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J. Pharmacol. Exp. Ther. 267:1993;538-547.
9. Klemm W.R. Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology (Berl.). 85:1985;139-142.
10. Matsui M., Araki Y., Karasawa H., Matsubara N., Taketo M.M., Seldin M.F. Mapping of five subtype genes for muscarinic acetylcholine receptor to mouse chromosomes. Genes & Genet. Syst. 74:1999;15-21.
11. 3 subtype. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9579-9584.
12. Olianas M.C., Onali P. Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease. Br. J. Pharmacol. 118:1996;827-828.
13. Saga Y., Kobayashi M., Ohta H., Murai N., Nakai N., Oshima M., Taketo M.M. Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRγ1 isoform. Genes Cells. 4:1999;219-228.
14. Shannon H.E., Peters S.C. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther. 255:1990;549-553.
15. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 64:1991;693-702.
16. 4) in rat forebrain. Mol. Pharmacol. 38:1990;267-273.
17. Yagi T., Ikawa Y., Yoshida K., Shigetani Y., Takeda N., Mabuchi I., Yamamoto T., Aizawa S. Homologous recombination at c-fyn locus of mouse embryonic stem cells with use of diphtheria toxin A-fragment gene in negative selection. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9918-9922.
18. Yasuda R.P., Ciesla W., Flores L.R., Wall S.J., Li M., Satkus S.A., Weisstein J.S., Spagnola B.V., Wolfe B.B. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol. Pharmacol. 43:1993;149-157.